Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalized B cells

Blood

Volumn 92, Issue 5, 1998, Pages 1721-1727

  Kenney, Jamie L ^b   Guinness, Mary E ^b   Curiel, Tyler ^b   Lacy, Jill ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; ETOPOSIDE; MEMBRANE PROTEIN; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL IMMORTALIZATION; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0032170456     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v92.5.1721.417a08_1721_1727     Document Type: Article

References (36)

1. Miller G: Epstein-Barr Virus - Biology, pathogenesis, and medical aspects, in Fields BN, Knipe DM, Chanock RM (eds): Virology. New York, N Y, Raven. 1990, p 1921
2. Pope JH: Transformation by the virus in vitro, in Epstein MA, Achong BG (eds): The Epstein-Barr Virus. New York, NY, Springer-Verlag, 1979, p 205
3. Middleton T, Gahn TA, Martin JM, Sugden B: Immortalizing genes of Epstein-Barr virus, in Maramorosch K, Murphy FA, Shatkin JA (eds): Advances in Viral Research. San Diego, CA, Academic, 1991, p 19
4. Kieff E, Liebowitz D: Epstein-Barr virus and its replication, in Fields BN, Knipe DM, Chanock RM (eds): Virology. New York, NY, Raven, 1990, p 1889
5. Speck SH, Strominger JL: Transcription of Epstein-Barr virus in latently infected, growth transformed lymphocytes, in Klein G (ed): Advances in Viral Oncology. New York, NY, Raven, 1989, p 133
6. Cohen JI, Wang F, Kieff E: Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol 65:2545, 1991
7. Hammerschmidt W, Sugden B: Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340:393, 1989
8. Kaye KM, Izumi KM, Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 90:9150, 1993
9. Tompkinson B, Robertson E, Kieff E: Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol 76:2014, 1993
10. Baichwal VR, Sugden B: Transformation of BALB 3T3 cells by the BNLFI gene of Epstein-Barr virus. Oncogene 2:461, 1988
11. Wang D, Liebowitz D, Kieff E: An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831, 1985
12. Dawson CW, Rickinson AB, Young LS: Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344:777, 1990
13. Wang F, Gregory C, Sample C, Rowe M, Liebowitz D, Murray R, Rickinson A, Kieff E: Epstein-Barr virus latent membrane protein (LMP1) and nuclear profeins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-1 and LMP1 cooperatively induce CD23. J Virol 64:2309, 1990
14. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R, Springer T, Kieff E: Epstein-Barr virus latent infection membrane protein alters the human B-lymphocytes phenotype: Deletion of the amino terminus abolished activity. J Virol 62:4173, 1988
15. Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E, Rickinson A: Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107, 1991
16. Okan I, Wang Y, Chen F, Hu L-F, Imreh S. KJein G, Wiman KG: The EBV-encoded LMP1 protein inhibits p53-triggered apoptosis but not growth arrest. Oncogene 11:1027, 1995
17. Laherty CD, Hu HM, Opipari AW, Wang F, Dixit VM: The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J Biol Chem 267:24157, 1992
18. Wang S, Rowe M, Lundgren E: Expression of Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the Bcl-2 homolog Mcl-1 levels in B-cell lines. Cancer Res 56:4610, 1996
19. Fennewald S, van Santen V, Kieff E: Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol 61:411, 1987
20. Roth G, Curiel T, Lacy J: Epstein-Barr viral nuclear antigen 1 antisense oligodeoxynucleotide inhibits proliferation of Epstein-Barr virus-immortalized B cells. Blood 84:582, 1994
21. Shah GM, Shah GR, Poirier GG: Different cleavage patterns for poly(ADP-ribose)polymerase during necrosis and apoptosis in HL-60 cells. Biochem Biophys Res Commun 229:838, 1996
22. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin NA, Yu VL, Miller DK: Identification and inhibition of the TCE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
23. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32 beta, a mammalian homolog of CED-3, is a Crm-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801, 1995
24. Li X, Darzynkiewicz Z: Labeling DNA strand breaks with BrdUTP. Detection of apoptosis and cell proliferation. Cell Prolif 28:573, 1995
25. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
26. Strasser A, Harris AW, Jacks T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 79:329, 1994
27. Dole M, Nunez G, Merchant AK, Maybaum J, Rode CK, Btoch CA, Castle VP: Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma, Cancer Res 54:3253, 1994
28. Kamesaki S, Kamesaki H, Jorgensen TJ, Tanizawa A, Pommier Y, Cossman J: Bcl-2 inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 53:4251, 1993
29. Murray PG, Swinnen LJ, Constandinou CM, Pyle JM, Can TJ, Hardwick JM, Amointfer R: Bcl-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders. Blood 87:706, 1996
30. Hamilton-Dutoit SJ, Rea D, Raphael M, Snadvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van Krieken JHJM, Pallesen G: Epstein-Barr virus-latent gene expression and tumor cell phenotype in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma. Correlation of lymphoma phenotype with three distinct patterns of viral latency. Am J Pathol 143:1072, 1993
31. Brooks L, Yao QY, Rickinson AB, Young LS: Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA-J, LMP-1 and LMP-2 transcripts. J Virol 66:2689, 1992
32. Fries KL, Miller WE, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through induction of the A20 gene. J Virol 70:8653, 1996
33. Baichwal VR, Sugden B: Posttranslation al processing of an Epstein-Barr virus-encoded membrane protein expressed in cells transformed by Epstein-Barr virus. J Virol 61:866-875, 1987
34. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, Van Elsas A, Muller M, Wolff K, Eichler H-G, Pehamberger H: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232, 1998
35. Bishop MR, Iversen PL, Bayever E, Sharp JG, Greiner TC, Copple BL, Ruddon R, Zon G, Spinolo J, Arneson M, Armitage JO, Kessinger A: Phase I trial of an antisense oligonucleotide OL(1) p53 in hematologic malignancies. J Clin Oncol 14:1320, 1996
36. Webb A, Cunningham D, Cotter F, Clarke PA, de Stefano F, Ross P, Corbo M, Dziewanowska Z: BCL-2 antisense therapy in patients with non-Hodgkin'siymprioma. Lancet 349:1137, 1997